Today The Eli Lilly and Company (LLY) Given a $100.00 Price Target at Citigroup Inc.

Today The Eli Lilly and Company (LLY) Given a $100.00 Price Target at Citigroup Inc.

Citigroup Inc. set a $100.00 price objective on Eli Lilly and Company (NYSE:LLY) in a research note released on Thursday. The firm currently has a buy rating on the stock.

Other equities research analysts also recently issued research reports about the company. Goldman Sachs Group, Inc. (The) raised Eli Lilly and Company from a neutral rating to a buy rating and raised their price target for the company from $89.00 to $95.00 in a report on Tuesday, September 27th. BMO Capital Markets reaffirmed a buy rating and set a $94.00 price target on shares of Eli Lilly and Company in a report on Monday, October 3rd. Zacks Investment Research raised Eli Lilly and Company from a hold rating to a buy rating and set a $89.00 price target for the company in a report on Tuesday, September 27th. Jefferies Group LLC reiterated a buy rating and set a $100.00 price objective (down previously from $105.00) on shares of Eli Lilly and Company in a research report on Friday, October 28th. Finally, Leerink Swann reiterated a buy rating and set a $103.00 price objective on shares of Eli Lilly and Company in a research report on Sunday, October 9th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of Buy and an average price target of $87.59.

Eli Lilly and Company (NYSE:LLY) opened at 74.85 on Thursday. The firm has a market cap of $79.17 billion, a P/E ratio of 32.56 and a beta of 0.25. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $83.79. The company’s 50-day moving average is $73.39 and its 200 day moving average is $77.07.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 10th. Investors of record on Wednesday, February 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Monday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $0.51. This represents a $2.08 annualized dividend and a yield of 2.78%. Eli Lilly and Company’s dividend payout ratio (DPR) is 88.70%.

In other Eli Lilly and Company news, Director R David Hoover acquired 500 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, December 16th. The shares were acquired at an average cost of $71.85 per share, with a total value of $35,925.00. Following the completion of the purchase, the director now directly owns 33,504 shares of the company’s stock, valued at approximately $2,407,262.40. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the firm’s stock in a transaction dated Friday, December 16th. The shares were sold at an average price of $72.59, for a total value of $14,518,000.00. Following the completion of the sale, the insider now directly owns 125,649,408 shares in the company, valued at $9,120,890,526.72. The disclosure for this sale can be found here. Insiders sold 222,335 shares of company stock worth $16,160,689 over the last ninety days. 0.20% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in LLY. Genesee Valley Trust Co. acquired a new stake in Eli Lilly and Company during the second quarter valued at $212,000. First Merchants Corp raised its stake in shares of Eli Lilly and Company by 247.1% in the second quarter. First Merchants Corp now owns 26,722 shares of the company’s stock worth $2,104,000 after buying an additional 19,024 shares during the last quarter. HL Financial Services LLC raised its stake in shares of Eli Lilly and Company by 0.3% in the second quarter. HL Financial Services LLC now owns 51,421 shares of the company’s stock worth $4,049,000 after buying an additional 149 shares during the last quarter. NewSquare Capital LLC raised its stake in shares of Eli Lilly and Company by 17.5% in the second quarter. NewSquare Capital LLC now owns 9,528 shares of the company’s stock worth $750,000 after buying an additional 1,419 shares during the last quarter. Finally, Wagner Bowman Management Corp raised its stake in shares of Eli Lilly and Company by 0.3% in the second quarter. Wagner Bowman Management Corp now owns 9,672 shares of the company’s stock worth $761,000 after buying an additional 29 shares during the last quarter. 74.88% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Related posts

Leave a Comment